Previous 10 | Next 10 |
The following slide deck was published by NGM Biopharmaceuticals, Inc. in conjunction with this event. For further details see: NGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow
Gainers: MorphoSys (MOR) +20%. NGM Biopharmaceuticals (NGM) +14%. National Vision Holdings (EYE) +10%. Editas Medicine (EDIT) +10%. Hyzon Motors (HYZN) +5%. Losers: Outset Medical (OM) -22%. Redbox Entertainment (RDBXW) -14%. Xperi Holding Corporation (XPER) -7%. C...
NGM Biopharmaceuticals (NASDAQ:NGM +3.8%) 10% owner and director David V. Goeddel buys 34,200 shares at ~$13.03 worth ~$450K. The stock has lost ~23% on a year-to-date basis, and has a market cap of ~$1.15B. Form 4 For further details see: NGM Biopharmaceuticals trades 4% higher on dire...
--NGM707, NGM Bio’s most advanced myeloid reprogramming antibody product candidate, will be showcased in the third of a four-part series titled the “Explorer Series”-- SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (...
NGM Biopharmaceuticals (NASDAQ:NGM) stock climbed as much as 10.2% on Monday after the firm disclosed certain insider buying. NGM disclosed that director and 10% owner Column Group bought ~166.4K shares at $10.73-$11.99 worth ~$1.9M in multiple transactions. Column Group now holds ~11.1M...
--Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA ® -- --All three of NGM Bio’s wholly-owned myeloid reprogramming product candidates ...
NGM Biopharmaceuticals press release (NASDAQ:NGM): Q1 GAAP EPS of -$0.42 in-line. Revenue of $20.95M (-2.9% Y/Y) beats by $6M. For further details see: NGM Biopharmaceuticals GAAP EPS of -$0.42 in-line, revenue of $20.95M beats by $6M
Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA ® (pembrolizumab), for the treatment of patients with advanced solid tumors Presented preclinical research for NGM707, a dual ILT2...
After last year's NASH flop, NGM was written off as a lost cause. The company has been able to turn itself around. Today it is an oncology-focused company with multiple interesting assets. For further details see: NGM Biopharmaceuticals: How They Changed A Dead End To A ...
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the second of four virtual R&D event...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...